Abstract

IntroductionThe Amsterdam PrEP project is a prospective, open‐label demonstration study at a large sexually transmitted infection (STI) clinic. We examined the uptake of PrEP; the baseline characteristics of men who have sex with men (MSM) and transgender persons initiating PrEP; their choices of daily versus event‐driven PrEP and the determinants of these choices.MethodsFrom August 2015 through May 2016, enrolment took place at the STI clinic of the Public Health Service of Amsterdam, the Netherlands. MSM or transgender persons were eligible if they had at least one risk factor for HIV infection within the preceding six months. Participants were offered a choice between daily or event‐driven use of tenofovir/emtricitabine. Baseline data were analysed using descriptive statistics and multivariable analysis was employed to determine variables associated with daily versus event‐driven PrEP.ResultsOnline applications were submitted by 870 persons, of whom 587 were invited for a screening visit. Of them, 415 were screened for eligibility and 376 initiated PrEP. One quarter (103/376, 27%) chose event‐driven PrEP. Prevalence of bacterial STI was 19.0% and mean condomless anal sex (CAS) episodes in the preceding three months were 11. In multivariable analysis, older age (≥45 vs. ≤34, aOR 2.1, 95% CI 1.2 to 3.9), being involved in a steady relationship (aOR 1.7, 95% CI 1.0 to 2.7), no other daily medication use (aOR 0.6, 95% CI 0.3 to 0.9), and fewer episodes of CAS (per log increase aOR 0.7, 95% CI 0.6 to 0.9) were determinants for choosing event‐driven PrEP.DiscussionPrEP programmes are becoming one of the more important intervention strategies with the goal of reducing incident HIV‐infection and we were unable to accommodate many of the persons applying for this study. Offering a choice of dosing regimen to PrEP users may enable further personalization of HIV prevention strategies and enhance up‐take, adherence and cost‐effectiveness.ConclusionsThe majority of participants preferred daily versus event‐driven use. Within this majority, a high number of CAS episodes before PrEP initiation was reported and we observed a high prevalence of STI. Determinants of choosing event‐driven PrEP were older age, fewer CAS episodes, no other daily medication use, and involved in a steady relationship.

Highlights

  • The Amsterdam pre-exposure prophylaxis (PrEP) project is a prospective, open-label demonstration study at a large sexually transmitted infection (STI) clinic

  • One to four weeks later at PrEP initiation, we verified that all diagnosed STI had been treated according to clinic protocols, and if not we provided immediate treatment; eligibility criteria were confirmed, a self-administered questionnaire was completed, and blood was taken to test for HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV) infections

  • To the best of our knowledge, we are the first to report on the preferences between daily and event-driven PrEP among men who have sex with men (MSM) and the reasons for such preferences

Read more

Summary

| INTRODUCTION

In the Netherlands, men who have sex with men (MSM) accounted for 65% of new HIV diagnoses in 2015 and HIV incidence has not been markedly declining [1] These findings indicate the urgent need for new methods of HIV prevention. We started the Amsterdam PrEP (AMPrEP) demonstration project with the aim of assessing uptake of daily and event-driven PrEP, at the participant’s discretion, among HIV-negative MSM and transgender persons at increased risk for HIV infection. This project was part of a comprehensive HIV-reduction package offered at a large STI clinic. We examined the predominant self-reported motives for PrEP use and choice of regimen, and analysed determinants for choosing event-driven PrEP use

| Application procedures and study site
| RESULTS
Findings
| DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call